Medicure Inc. (MPH) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Medicare's earnings conference call for the quarter ended March 31, 2025. My name is Jenny and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events, and expectations which are made pursuant to the Safe Harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, those described in the company's most recent Annual Information Form and Form 20F. Later, we will conduct a question and answer session. Please note this conference is being recorded and today's date is May 22, 2025. I would now like to turn the conference over to Dr. Albert Friesen, Chief Executive Officer of Medicure Incorporated. Please go ahead, Dr. Friesen. Thank you, Jenny, and good morning to all on the call. We appreciate your interest and participation in today's call. Joining me today, excuse me, Joining me today on the Q1 2025 financial statements call is Dr. Neil Owens, President and Chief Operating Officer, and Horace Uden, Medicare's Chief Financial Officer. The net revenue for Q1 2025 was 5.5 million, a slight decrease from the previous year's net revenue, which was 5.7. The company recorded a net loss for Q1 of approximately $694,000 or $0.07 per share compared to a net income of $51,000 the first quarter of 2024. The net loss in the current period was due in large part due to significant R&D expenses of $570,000 mainly for the MC1 PNPO clinica...